drugset / Trial / NCT01484587

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

NCT01484587

Phase 1 Completed 24 enrolled Janssen Pharmaceutical K.K.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of CNTO 1959 following a single subcutaneous (SC, under the skin) dose administered to Japanese participants with moderate to severe plaque psoriasis.

Timeline

Start
2011-08-22
Primary completion
2013-04-11
Completion
2013-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody 10 mg Subcutaneous
Subject Guselkumab Monoclonal antibody 30 mg Subcutaneous
Subject Guselkumab Monoclonal antibody 100 mg Subcutaneous
Subject Guselkumab Monoclonal antibody 300 mg Subcutaneous

Indications